The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Diiodothyropropionic Acid (DITPA) in the Treatment of MCT8 Deficiency
Open accessAbstract
CONTEXT: Monocarboxylate transporter 8 (MCT8) is a thyroid hormone-specific cell membrane transporter. MCT8 deficiency causes severe psychomotor retardation and abnormal thyroid tests. The great majority of affected children cannot walk or talk, and all have elevated serum T(3) levels, causing peripheral tissue hypermetabolism and inability to maintain weight. Treatment with thyroid hormone is ineffective. In Mct8-deficient mice, the thyroid hormone analog, diiodothyropropionic acid (DITPA), does not require MCT8 to enter tissues and could be an effective alternative to thyroid hormone treatment in humans. OBJECTIVE: The objective of the study was to evaluate the effect and efficacy of DITPA in children with MCT8 deficiency. METHODS: This was a multicenter report of four affected children given DITPA on compassionate grounds for 26-40 months. Treatment was initiated at ages 8.5-25 months, beginning with a small dose of 1.8 mg, increasing to a maximal 30 mg/d (2.1-2.4 mg/kg · d), given in three divided doses. RESULTS: DITPA normalized the elevated serum T(3) and TSH when the dose reached 1 mg/kg · d and T(4) and rT(3) increased to the lower normal range. The following significant changes were also observed: decline in SHBG (in all subjects), heart rate (in three of four), and ferritin (in one of four). Cholesterol increased in two subjects. There was no weight loss and weight gain occurred in two. None of the treated children required a gastric feeding tube or developed seizures. No adverse effects were observed. CONCLUSION: DITPA (1-2 mg/kg · d) almost completely normalizes thyroid tests and reduces the hypermetabolism and the tendency for weight loss. The effects of earlier commencement and long-term therapy remain to be determined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the lack of neurological improvement in response to DITPA treatment, which was at doses 1,000-fold higher than replacement doses of T3, may also be due to the late treatment initiation of MCT8-deficient patients (at ages of 9–21 months) (Verge et al., 2012).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Verge et al., 2012
In the citing paper
“As an example, DITPA is a TH analog that can activate the T3 signaling cascade and has been tested in animal models and MCT8-deficient patients (Ferrara et al., 2015; Verge et al., 2012).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Verge et al., 2012
Citations
Cites
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter
Friesema, E. C. H., Ganguly, S., Abdalla, A., Fox, J. E. M., Halestrap, A. P., & Visser, T. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300909200 · Cited by 725
Friesema, E. C., Grueters, A., Biebermann, H., Krude, H., von Moers, A., Reeser, M., Barrett, T. G., Mancilla, E. E., Svensson, J., Kester, M. H., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17226-7 · Cited by 709
Dumitrescu, A. M., Liao, X.-H., Best, T. B., Brockmann, K., & Refetoff, S. (2004) · The American Journal of Human Genetics · doi:10.1086/380999 · Cited by 706
Self-citationMinireview: Thyroid Hormone Transporters: The Knowns and the Unknowns
Visser, W. E., Friesema, E. C. H., & Visser, T. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0095 · Cited by 390
Allan-Herndon-Dudley Syndrome and the Monocarboxylate Transporter 8 (MCT8) Gene
Schwartz, C. E., May, M. M., Carpenter, N. J., Rogers, R. C., Martin, J. A., Bialer, M. G., Ward, J. C., Sanabria, J., Marsa, S., Lewis, J. A., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/431313 · Cited by 377
Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8
Trajkovic, M., Visser, T. J., Mittag, J., Horn, S., Lukas, J., Darras, V. M., Raivich, G., Bauer, K., & Heuer, H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28253 · Cited by 353
Dumitrescu, A. M., Liao, X.-H., Weiss, R. E., Millen, K., & Refetoff, S. (2006) · Endocrinology · doi:10.1210/en.2006-0390 · Cited by 318
Self-citationMice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion
Cosmo, C. D., Liao, X.-H., Dumitrescu, A. M., Philp, N. J., Weiss, R. E., & Refetoff, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42113 · Cited by 198
Self-citationPathophysiological Importance of Thyroid Hormone Transporters
Heuer, H., & Visser, T. J. (2009) · Endocrinology · doi:10.1210/en.2008-1518 · Cited by 148
The MCT8 thyroid hormone transporter and Allan–Herndon–Dudley syndrome
Schwartz, C. E., & Stevenson, R. E. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.03.009 · Cited by 146
Flagged first, then by citations
Research works printed but not linked: 1
- Allan, 1944, Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly., Am J Ment Defic, 48, 325
Cited by
Sorted by citations
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
“Treatment with diiodothyropropionic acid (DITPA), in animal models and humans with inactivation or mutation in the MCT8 gene, results in reduction in serum TSH and serum T3, and an improvement in hypermetabolism with weight gain and reduced caloric needs (60, 262).”
BackgroundJonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“These individuals have peripheral hypermetabolism and abnormal serum thyroid levels with elevated serum T3, low serum T4, and slightly high TSH (486,500,501).”
Paradigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293
Self-citationTreatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Thyroid hormone signaling in energy homeostasis and energy metabolism
McAninch, E. A., & Bianco, A. C. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12374 · Cited by 245
Vatine, G. D., Al-Ahmad, A., Barriga, B. K., Svendsen, S., Salim, A., Garcia, L., Garcia, V. J., Ho, R., Yucer, N., Qian, T., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.04.002 · Cited by 233
“Diiodothyropropionic acid (DITPA), currently under clinical investigation in MCT8-deficient patients (Verge et al., 2012), provides rescue of some of the thyroid phenotypes.”
BackgroundInfluentialSelf-citationGroeneweg, S., van Geest, F. S., Peeters, R. P., Heuer, H., & Visser, W. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz008 · Cited by 216
“When L-T4 (typically 100 µg/d) was added, serum thyroid function tests largely normalized and the thyrotoxic state in peripheral tissues was alleviated, as evidenced by improvement in body weight, heart rate, and serum markers of tissue thyroid hormone state (341, 357).”
BackgroundInfluentialBianco, A. C., Anderson, G., Forrest, D., Galton, V. A., Gereben, B., Kim, B. W., Kopp, P. A., Liao, X. H., Obregon, M. J., Peeters, R. P., et al. (2014) · Thyroid · doi:10.1089/thy.2013.0109 · Cited by 205
Groeneweg, S., Peeters, R. P., Moran, C., Stoupa, A., Auriol, F., Tonduti, D., Dica, A., Paone, L., Rozenkova, K., Malikova, J., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30155-x · Cited by 129
Thyrotropin secretion patterns in health and disease
Roelfsema, F., & Veldhuis, J. D. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1076 · Cited by 113
Kersseboom, S., Horn, S., Visser, W. E., Chen, J., Friesema, E. C. H., Vaurs‐Barrière, C., Peeters, R. P., Heuer, H., & Visser, T. J. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1135 · Cited by 96
Liu, Y., & Brent, G. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.007 · Cited by 93
“DITPA treatment in humans with Mct8 gene mutations is effective at correcting thyroid function tests and the hypermetabolism, with reduction in serum T3 and weight gain, although does not reverse the neurological deficits (Verge et al., 2012).”
Zada, D., Tovin, A., Lerer-Goldshtein, T., Vatine, G. D., & Appelbaum, L. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004615 · Cited by 92
“Indeed, DITPA has been tested in adult MCT8-KO mouse and administered to several AHDS patients [49,50].”
MethodThyroid Hormone Analogues: An Update
Zucchi, R. (2020) · Thyroid · doi:10.1089/thy.2020.0071 · Cited by 88
“4 mg/kg per day) was able to normalize T3 in four children affected by MCT8 deficiency, aged 8–25 months (34).”
BackgroundRemérand, G., Boespflug‐Tanguy, O., Tonduti, D., Touraine, R. L., Rodriguez, D., Curie, A., Perreton, N., Portes, V. D., Sarret, C., & RMLX/AHDS Study Group (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14332 · Cited by 87
Horn, S., Kersseboom, S., Mayerl, S. E., Müller, J., Groba, C., Trajkovic‐Arsic, M., Ackermann, T., Visser, T. J., & Heuer, H. (2013) · Endocrinology · doi:10.1210/en.2012-1628 · Cited by 84
“Moreover, application of DITPA to 4 patients with MCT8 mutations resulted in a normalization of the serum TH parameters without causing any overt side effects (21).”
Disorder of thyroid hormone transport into the tissues
Groeneweg, S., Visser, W. E., & Visser, T. J. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.05.001 · Cited by 75
Thyroid Hormone Transport and Transporters
Braun, D., & Schweizer, U. (2018) · Vitamins and Hormones · doi:10.1016/bs.vh.2017.04.005 · Cited by 74
Zada, D., Tovin, A., Lerer‐Goldshtein, T., & Appelbaum, L. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.027227 · Cited by 64
“…demonstrated that TH analogs, i.e. 3,3′,5-triiodothyroacetic acid (TRIAC; TA3) and 3,5-diiodothyropropionic acid (DITPA), can cross the cell membrane even in the absence of Mct8 (Di Cosmo et al., 2009; Kersseboom et al., 2014; Messier and Langlois, 2000; Verge et al., 2012; Verhoeven et al., 2002).”
BackgroundGroeneweg, S., Peeters, R. P., Visser, T. J., & Visser, W. E. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.029 · Cited by 65
“However, several markers of peripheral TH 249 action, including serum SHBG, heart rate and body weight showed variable responses among the 250 patients (Verge et al., 2012).”
Hypomyelinating leukodystrophies — a molecular insight into the white matter pathology
Charzewska, A., Wierzba, J., Iżycka‐Świeszewska, E., Bekiesińska‐Figatowska, M., Jurek, M., Gintowt, A., Kłosowska, A., Bal, J., & Hoffman‐Zacharska, D. (2016) · Clinical Genetics · doi:10.1111/cge.12811 · Cited by 60
“It almost completely normalizes thyroid tests and reduces hypermetabolism and the tendency to weight loss (56).”
BackgroundPersani, L., Rodien, P., Moran, C., Visser, W., Groeneweg, S., Peeters, R. P., Refetoff, S., Gurnell, M., Beck-Peccoz, P., & Chatterjee, K. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0125 · Cited by 39
“(122).”
Self-citationMCT8 Deficiency: The Road to Therapies for a Rare Disease
Grijota-Martínez, C., Bárez‐López, S., Gómez‐Andrés, D., & Guadaño‐Ferraz, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00380 · Cited by 52
Cosmo, C. D., Liao, X.-H., Ye, H., Ferrara, A. M., Weiss, R. E., Refetoff, S., & Dumitrescu, A. M. (2013) · Endocrinology · doi:10.1210/en.2013-1150 · Cited by 45
“A recent publication showed a close correlation between T3 levels and body mass index in two twins with MCT8 deficiency, who showed an improvement in an SD score of weight with the decline of T3 during treatment with the TH analog diiodothyropropionic acid (8).”
BackgroundSelf-citationTolcos, M., Petratos, S., Hirst, J. J., Wong, F. Y., Spencer, S. J., Azhan, A., Emery, B., & Walker, D. W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.009 · Cited by 46
“Importantly, this DITPA dose was well tolerated by the children and, as in mice, did not have thyrotoxic effects on peripheral organs (Verge et al., 2012), making it an attractive option for therapeutic intervention.”
BackgroundInfluentialPagnin, M., Kondos‐Devcic, D., Chincarini, G., Cumberland, A. L., Richardson, S. J., & Tolcos, M. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100901 · Cited by 47
Spatiotemporal Changes of Cerebral Monocarboxylate Transporter 8 Expression
Wilpert, N., Krueger, M., Opitz, R., Sebinger, D., Paisdzior, S., Mages, B., Schulz, A., Spranger, J., Wirth, E. K., Stachelscheid, H., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0544 · Cited by 47
Monocarboxylate Transporter 8 Deficiency: Delayed or Permanent Hypomyelination?
Vancamp, P., DEMENEIX, B. A., & Remaud, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00283 · Cited by 43
van Geest, F. S., Gunhanlar, N., Groeneweg, S., & Visser, W. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.723750 · Cited by 41
Inherited defects in thyroid hormone cell-membrane transport and metabolism
Fu, J., & Dumitrescu, A. M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.014 · Cited by 41
Self-citationIwayama, H., Liao, X.-H., Braun, L., Bárez‐López, S., Kaspar, B. K., Weiss, R. E., Dumitrescu, A. M., Guadaño‐Ferraz, A., & Refetoff, S. (2016) · Thyroid · doi:10.1089/thy.2016.0060 · Cited by 41
“propylthiouracil (PTU), or the thyromimetic compound diiodothyropropionic acid (DITPA) reduces the hypermetabolism and ameliorates nutrition, but does not produce significant neurodevelopmental improvements (9,10).”
BackgroundSelf-citationThyroid hormone metabolites and analogues
Senese, R., Cioffi, F., Petito, G., Goglia, F., & Lanni, A. (2019) · Endocrine · doi:10.1007/s12020-019-02025-5 · Cited by 41
Sundaram, S. M., Pereira, A. A., Müller‐Fielitz, H., Köpke, H., Angelis, M. D., Müller, T. D., Heuer, H., Körbelin, J., Krohn, M., Mittag, J., et al. (2022) · Brain · doi:10.1093/brain/awac243 · Cited by 44
“The TH analogues 3,5-diiodothyropropionic acid (DITPA) and 3,3 ′ ,5-triiodothyroacetic acid (TRIAC) improved the peripheral thyroid status, 12,13 but treat-ment of the CNS symptoms that are key to patients’ disabilities is still not available and represents an unmet medical need.”
Lee, J. Y., Kim, M. J., Deliyanti, D., Azari, M. F., Rossello, F. J., Costin, A. J., Ramm, G., Stanley, E. G., Elefanty, A. G., Wilkinson‐Berka, J. L., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.016 · Cited by 38
“…resolution of peripheral hyperthyroid symptoms but their effect on human CNS cell development and importantly, clinical evidence of specific cognitive improvements, are still lacking (Verge et al., 2012; Kersseboom et al., 2014; Groeneweg et al., 2017; Ferrara et al., 2015; Ferrara et al., 2014).”
BackgroundMethodInfluentialEffect of Triiodothyroacetic Acid Treatment in Mct8 Deficiency: A Word of Caution
Bárez‐López, S., Obregón, M.-J., de Mena, R. M., Bernal, J., Guadaño‐Ferraz, A., & Morte, B. (2015) · Thyroid · doi:10.1089/thy.2015.0388 · Cited by 39
Defects of Thyroid Hormone Synthesis and Action
Hannoush, Z. C., & Weiss, R. E. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.005 · Cited by 39
“defect by using alternative transporters has been studied with promising outcomes that need further investigation [74, 75].”
BackgroundSelf-citationNovara, F., Groeneweg, S., Freri, E., Estienne, M., Reho, P., Matricardi, S., Castellotti, B., Visser, W. E., Zuffardi, O., & Visser, T. J. (2016) · Human Mutation · doi:10.1002/humu.23140 · Cited by 38
“Beneficial effects on TFTs have also been observed in AHDS patients treated with the T3 analogue DITPA [Verge et al., 2012].”
BackgroundDifferent causes of Reduced Sensitivity to Thyroid Hormone: Diagnosis and Clinical management
Visser, W. E., van Mullem, A. A., Visser, T. J., & Peeters, R. P. (2013) · Clinical Endocrinology · doi:10.1111/cen.12281 · Cited by 37
Inherited defects of thyroid hormone-cell-membrane transport
Fu, J., Refetoff, S., & Dumitrescu, A. M. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000432531.03233.ad · Cited by 36
Self-citationMonocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment
van Geest, F. S., Groeneweg, S., & Visser, W. E. (2021) · Endocrine · doi:10.1007/s12020-020-02603-y · Cited by 34
MCT8 deficiency in Purkinje cells disrupts embryonic chicken cerebellar development
Delbaere, J., Vancamp, P., Herck, S. L. J. V., Bourgeois, N. M. A., Green, M. J., Wingate, R. J. T., & Darras, V. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0323 · Cited by 34
“2014), a recent clinical trial in patients treated in the first year of infancy failed to improve mental status, probably because neurological damage was already irreversible at the onset of treatment (Verge et al. 2012).”
BackgroundThyroid Hormone Transporters in Pregnancy and Fetal Development
Chen, Z., Meima, M. E., Peeters, R. P., & Visser, W. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315113 · Cited by 35
“Among them, treatment with thyroid hormone analogs 3,5-diiodothyropropionic acid (DITPA) or 3,3′,5-tri-iodothyroacetic acid (TRIAC) improved the peripheral phenotype [57,58].”
BackgroundArmour, C. M., Kersseboom, S., Yoon, G., & Visser, T. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139343 · Cited by 34
“Though the first thyromimetic (DITPA) study in MCT8 patients did not improve cognitive development, it improved peripheral thyrotoxicosis [28].”
BackgroundThe Role of Thyroid Hormone in Neuronal Protection
Liu, Y., & Brent, G. A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200019 · Cited by 45
“Treatment with diiodothyropropionic acid (DITPA), a thyroid hormone analog, that bypass the transporter to enter the brain, has not been shown effectiveness in promoting neurological improvement (175), but does result in reduction in serum T3 and marked improvement of the associated hypermetabolism.”
Vancamp, P., & Darras, V. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.11.023 · Cited by 34
The Thyroid Hormone Analog DITPA Ameliorates Metabolic Parameters of Male Mice With Mct8 Deficiency
Ferrara, A. M., Liao, X.-H., Ye, H., Weiss, R. E., Dumitrescu, A. M., & Refetoff, S. (2015) · Endocrinology · doi:10.1210/en.2015-1234 · Cited by 32
Self-citationPrenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation
Refetoff, S., Παππά, Θ., Williams, M. K., Matheus, M. G., Liao, X.-H., Hansen, K., Nicol, L. E., Pierce, M. J., Blasco, P. A., Jensen, M. W., et al. (2020) · Thyroid · doi:10.1089/thy.2020.0306 · Cited by 31
Self-citationSobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain
Bárez‐López, S., Hartley, M. D., Grijota-Martínez, C., Scanlan, T. S., & Guadaño‐Ferraz, A. (2018) · Thyroid · doi:10.1089/thy.2018.0008 · Cited by 32
“The available treatments consist of a combination of levothyroxine (LT4) and propylthiouracil (PTU) (20), or the TH analog 3,5-diiodothyropropionic acid (DITPA) (21).”
BackgroundBraun, D., & Schweizer, U. (2015) · Endocrinology · doi:10.1210/en.2015-1393 · Cited by 28
Genetic disorders of thyroid metabolism and brain development
Kurian, M. A., & Jungbluth, H. (2014) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12445 · Cited by 25
“Increased ferritin and decreased cholesterol levels have been observed in some individuals.(30)”
BackgroundPlacenta Passage of the Thyroid Hormone Analog DITPA to Male Wild-Type and Mct8-Deficient Mice
Ferrara, A. M., Liao, X.-H., Gil-Ibáñez, P., Bernal, J., Weiss, R. E., Dumitrescu, A. M., & Refetoff, S. (2014) · Endocrinology · doi:10.1210/en.2014-1085 · Cited by 26
“The capacity of DITPA to cross the placenta, to enter fetal tissues, and to mimic TH action at pituitary and cortical levels in addition to the beneficial effects on the hypermetabolism already described in humans (7), makes this compound particularly suitable for prenatal treatment of MCT8 deficiency in humans.”
BackgroundInfluentialSelf-citationTreatment of congenital thyroid dysfunction: Achievements and challenges
Krude, H., Kühnen, P., & Biebermann, H. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.004 · Cited by 25
Impaired Sensitivity to Thyroid Hormone: Defects of Transport, Metabolism and Action
Dumitrescu, A. M., & Refetoff, S. (2015) · Cited by 24
Self-citationLiao, X.-H., Avalos, P., Shelest, O., Ofan, R., Shilo, M., Bresee, C. J., Likhite, S. B., Vit, J., Heuer, H., Kaspar, B. K., et al. (2022) · Thyroid · doi:10.1089/thy.2022.0034 · Cited by 24
“In patients with AHDS, DITPA (46) and TRIAC (47) reduced the high serum T 3 concentration; however, there was no evidence for improvement in neurological symptoms.”
Self-citationOligodendroglial Lineage Cells in Thyroid Hormone-Deprived Conditions
Kim, M. J., & Petratos, S. (2019) · Stem Cells International · doi:10.1155/2019/5496891 · Cited by 24
“In AHDS patients, elevated levels of serum T3 occur causing hypermetabolism in peripheral tissues, whereas reduced T3 within the brain establishes a hypothyroid state within the CNS [95].”
BackgroundInfluentialEmamnejad, R., Pagnin, M., & Petratos, S. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105788 · Cited by 25
“…DITPA is that it has the unique capacity to bypass the main TH transporter, monocarboxylate transporter 8 (MCT8), located within the blood-brain barrier (BBB) and the plasma membrane (Verge et al., 2012), a property that establishes it as an excellent candidate in a drug development program for MS.”
Anık, A., Kersseboom, S., Demir, K., Çatlı, G., Yiş, U., Böber, E., van Mullem, A. A., van Heerebeek, R., Kurul, S. H., Abacı, A., et al. (2014) · Hormone Research in Paediatrics · doi:10.1159/000365191 · Cited by 23
Braun, D., & Schweizer, U. (2016) · Endocrinology · doi:10.1210/en.2016-1530 · Cited by 23
“Diiodothyropropionic acid is reported to normalize the serum parameters of thyroid hormone function and allow weight gain, but improvements in neurologic impairment remained difficult to assess (46).”
BackgroundZebrafish – An emerging model to explore thyroid hormone transporters and psychomotor retardation
Zada, D., Blitz, E., & Appelbaum, L. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.004 · Cited by 23
Admati, I., Wasserman-Bartov, T., Tovin, A., Rozenblat, R., Blitz, E., Zada, D., Lerer‐Goldshtein, T., & Appelbaum, L. (2019) · Thyroid · doi:10.1089/thy.2019.0320 · Cited by 24
Salas-Lucia, F., Escamilla, S., Bianco, A. C., Dumitrescu, A. M., & Refetoff, S. (2024) · JCI Insight · doi:10.1172/jci.insight.174645 · Cited by 25
Self-citationKim, J. H., Kim, Y., Yum, M., Choi, J., Lee, B. H., Kim, G.-H., & Yoo, H. (2015) · Hormone Research in Paediatrics · doi:10.1159/000371466 · Cited by 19
Hypotonic male infant and MCT8 deficiency - a diagnosis to think about
Rodrigues, F., Grenha, J., Ortez, C., Nascimento, A., Morte, B., Belinchón, M. M., Armstrong, J., & Colomer, J. (2014) · BMC Pediatrics · doi:10.1186/1471-2431-14-252 · Cited by 19
“Some AHDS patients have been treated with TH supplementation, propylthiouracil or diiodothyropropionic acid; the last two result in better thyroid function tests, but without any improvement of motor or cognitive skills [19-21].”
MethodSchweizer, U., Towell, H., Vit, A., Rodriguez-Ruiz, A., & Steegborn, C. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.026 · Cited by 18
A Transgenic Mouse Model for Detection of Tissue-Specific Thyroid Hormone Action
Mohácsik, P., Erdélyi, F., Baranyi, M., Botz, B., Szabó, G., Tóth, M., Haltrich, I., Helyes, Z., Sperlágh, B., Tóth, Z., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00582 · Cited by 18
“The discovery of cellular mechanisms that allow for tissue specificity of TH action inspired the development of TR isoform- and tissue-specific TH analogs (16, 17).”
BackgroundChen, J., Salveridou, E., Liebmann, L., Sundaram, S. M., Doycheva, D., Markova, B., Hübner, C. A., Boelen, A., Visser, W. E., Heuer, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043452 · Cited by 17
“In a compassionate study, Ditpa was given for 26–40 months to four affected children at the age of 8–25 months and was able to both normalize high serum T3 concentrations and reduce symptoms of hypermetabolism [18].”
BackgroundGroeneweg, S., van den Berge, A., Meima, M. E., Peeters, R. P., Visser, T. J., & Visser, W. E. (2018) · Endocrinology · doi:10.1210/en.2017-00846 · Cited by 18
Disorders of the thyroid in the newborn and infant
Vliet, G. V., & Deladoëy, J. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00016-0 · Cited by 16
Therapeutic applications of thyroid hormone analogues
Visser, W. E. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.03.004 · Cited by 16
Triiodothyroacetic Acid Treatment in MCT8 Deficiency: A Word of Nuance
Visser, W. E., Heuer, H., & Visser, T. J. (2016) · Thyroid · doi:10.1089/thy.2016.0191 · Cited by 15
“Subsequently, some patients were treated with DITPA, with improvement of serum T3 concentrations and markers of peripheral T3 action (12).”
Trophic Factor, Nutritional, and Hormonal Regulation of Brain Development
Pleasure, J. R., Pleasure, D., & Pleasure, S. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-35214-7.00133-5 · Cited by 14
Finding the Way into the Brain without MCT8
Visser, W. E., & Visser, T. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3759 · Cited by 14
Bárez‐López, S., Grijota-Martínez, C., Liao, X.-H., Refetoff, S., & Guadaño‐Ferraz, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226017 · Cited by 16
“Patients have also been treated with the TH analog 3,5-diiodothyropropionic acid (DITPA), which is an agonist of the T3 nuclear receptor [14].”
MethodSelf-citationEmamnejad, R., Dass, M., Mahlis, M., Bozkurt, S., Ye, S., Pagnin, M., Theotokis, P., Grigoriadis, N., & Petratos, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.934971 · Cited by 14
“For example, DITPA can normalize peripheral hyperthyroidism and reduce hypermetabolism in AHDS patients.”
BackgroundResultInfluentialWilpert, N., Tonduti, D., Vaia, Y., Krude, H., Sarret, C., & Schuelke, M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s379703 · Cited by 13
“14 23, 25 Whether the reported Concluding considerations for development of therapies for MCT8 deficiency: (i) The full downstream effects of SLC16A2 mutations are not yet fully understood.”
BackgroundUnmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review
Bauer, A. J., Auble, B. A., Clark, A. L., Hu, T. Y., Isaza, A. R., McNerney, K. P., Metzger, D. L., Nicol, L. E., Pierce, S. R., & Sidlow, R. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1444919 · Cited by 13
“DITPA (diiodothyropropionic acid) is a synthetic T3 analog that can enter the CNS independent of MCT8 and stimulate thyroid hormone action by binding to the thyroid hormone receptors, TR α and TR β (45, 47).”
BackgroundKrude, H., Biebermann, H., Schuelke, M., Müller, T. D., & Tschöp, M. H. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1108-1456 · Cited by 12
The Influence of Thyroid Hormone on Growth Hormone Secretion and Action
Leung, A. M., & Brent, G. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-28038-7_4 · Cited by 13
Valcárcel-Hernández, V., Guillén-Yunta, M., Scanlan, T. S., Bárez‐López, S., & Guadaño‐Ferraz, A. (2023) · Thyroid · doi:10.1089/thy.2022.0612 · Cited by 12
Intranasal delivery of Thyroid hormones in MCT8 deficiency
Grijota-Martínez, C., Bárez‐López, S., Ausó, E., Refetoff, S., Frey, W. H., & Guadaño‐Ferraz, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236113 · Cited by 12
Self-citationValcárcel-Hernández, V., Guillén-Yunta, M., Bueno-Arribas, M., Montero‐Pedrazuela, A., Grijota-Martínez, C., Markossian, S., García-Aldea, Á., Flamant, F., Bárez‐López, S., & Guadaño‐Ferraz, A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105896 · Cited by 13
“reported to be epilepsy-prone (Vaurs-Barrière et al., 2009; Verge et al., 2012) consistent with our current findings in the P253L mice, alterations in the GABAergic system could be underlying the predisposition to epilepsy in some patients.”
BackgroundResultToward a treatment for thyroid hormone transporter MCT8 deficiency – achievements and challenges
Markova, B., Mayerl, S. E., & Heuer, H. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0286 · Cited by 10
Chan, S. L., Refetoff, S., Babić, N., Jin, M., Garg, U. C., & Yeo, K.-T. J. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab124 · Cited by 10
Self-citationTsh Induces Agrp1 Neuron Proliferation in Oatp1c1-Deficient Zebrafish
Wasserman-Bartov, T., Admati, I., Lebenthal-Loinger, I., Sharabany, J., Lerer‐Goldshtein, T., & Appelbaum, L. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0002-22.2022 · Cited by 10
Gurnell, M., Visser, T. J., Beck‐Peccoz, P., & Chatterjee, K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00095-0 · Cited by 9
Brent, G. A. (2013) · Thyroid · doi:10.1089/thy.2013.0679 · Cited by 10
“Thyroid hormone transport by moncarboxylate transporter 8 (Mct8) has gone from characterization in basic studies, to clinical studies identifying Mct8 gene mutations in patients with severe psychomotor retardation and abnormal thyroid function studies, to mouse models of Mct8 mutations, and then back to clinical treat…”
BackgroundChincarini, G., Walker, D. W., Wong, F. Y., Richardson, S. J., Cumberland, A. L., & Tolcos, M. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16124 · Cited by 7
“…boys with AHDS (congenital MCT8 mutation) have reported overall positive outcomes and ameliorated peripheral thyrotoxicosis (Groeneweg et al., 2019; Verge et al., 2012 ); follow-up trials evaluating the long-term neurodevelopmental outcomes following early life intervention are currently ongoing…”
InfluentialCheetham, T. D., & Wood, C. L. (2024) · Clinical Endocrinology · doi:10.1111/cen.15110 · Cited by 7
“51,52 A key question is whether early treatment will impact on neurodevelopmental outcome. that can include attention deficit hyperactivity disorder (ADHD).”
An in vivo accelerated developmental myelination model for testing promyelinating therapeutics
Lariosa-Willingham, K. D., Leonoudakis, D., Bragge, T., Tolppanen, L., Nurmi, A., Flanagan, M., Gibson, J., Wilson, D. L., Stratton, J., Lehtimäki, K. K., et al. (2022) · BMC Neuroscience · doi:10.1186/s12868-022-00714-y · Cited by 7
Interpreting Minor Variations in Thyroid Function or Echostructure
Vliet, G. V., & Deladoëy, J. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.008 · Cited by 7
Thyroid Hormone Analogs: Recent Developments
Freund, M., van Geest, F. S., Groeneweg, S., van Geest, F. S., & Visser, W. E. (2025) · Thyroid · doi:10.1089/thy.2025.0245 · Cited by 6
Schreiner, F., Vollbach, H., Sonntag, N., Schempp, V., Gohlke, B. C., Friese, J., Woelfle, J., Braun, D., & Schweizer, U. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae356 · Cited by 6
Diagnostic and Therapeutic Challenges in the Allan—Herndon—Dudley Syndrome
Groeneweg, S., Peeters, R. P., Visser, T. J., & Visser, W. E. (2016) · US Endocrinology · doi:10.17925/use.2016.12.02.90 · Cited by 6
Iwayama, H., Tanaka, T., Aoyama, K., Moroto, M., Adachi, S., Fujisawa, Y., Matsuura, H., Takano, K., Mizuno, H., & Okumura, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.657820 · Cited by 6
Syndromes of Impaired Sensitivity to Thyroid Hormone
Weiss, R. E., Dumitrescu, A. M., & Refetoff, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800892-8.00009-9 · Cited by 6
Self-citationWilpert, N., Hewitt, A. L., Pons, R. M., Henke, M., Dell’Orco, A., Bauer, M., Grolik, C., Menz, S., Wahle, M., Zink, A., et al. (2025) · Movement Disorders · doi:10.1002/mds.30152 · Cited by 6
Glycerol Phenylbutyrate Treatment of 2 Patients With Monocarboxylate Transporter 8 Deficiency
Zung, A., Sonntag, N., Schweizer, U., Banne, E., & Braun, D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae146 · Cited by 5
Identification of Human TRIAC Transmembrane Transporters
Becker, P. C., Güth-Steffens, M., Lazarow, K., Sonntag, N., Braun, D., Masfaka, S., Renko, K., Schomburg, L., Köhrle, J., von Kries, J. P., et al. (2024) · Thyroid · doi:10.1089/thy.2023.0592 · Cited by 6
Funkquist, A., Bengtsson, A. A., Johansson, P., Svensson, J., Bjellerup, P., Blennow, K., Wandt, B., & Sjöberg, S. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100218 · Cited by 5
“The monocarboxylate transporter 8 (MCT8) [16,29] is a specific transporter for thyroid hormones (TH) into the CNS. Allan-HerndonDudleys Syndrome (AHDS) is a disease specifically with - a MCT8 mutation [30].”
BackgroundInfluentialScholtes, N., Jelesch, E., Diesener, P., Stoffels, J., & Völkl, T. M. K. (2024) · Neuropediatrics · doi:10.1055/a-2502-6417 · Cited by 4
Metadata
- Authors
- Verge, C. F., Konrad, D., Cohen, M., Di Cosmo, C., Dumitrescu, A. M., Marcinkowski, T., Hameed, S., Hamilton, J., Weiss, R. E., & Refetoff, S.
- Affiliations
- UNSW Sydney (AU)
- University Children's Hospital Zurich (CH)
- Hospital for Sick Children (CA)
- Departments of Medicine (C.D.C., A.M.D., T.M., R.E.W., S.R.), Chicago, Illinois 60637
- Pediatrics (R.E.W., S.R.), Chicago, Illinois 60637
- University of Chicago (US)
- Corresponding author
- Refetoff, Samuel
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-12-01
- Volume
- 97
- Issue
- 12
- Pages
- 4515-4523
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3513545
- OpenAlex
- W2123696673
- Cited by
- 134
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 16 · 2023: 4 · 2022: 9 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 5 · 2017: 13 · 2016: 11 · 2015: 13 · 2014: 14 · 2013: 12 · 2012: 2
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pediatric Endocrine Society
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R37-DK 15070, P60DK20595, R37DK015070, F32DK091016, P60DK020595)
- National Center for Research Resources (5M01RR04999)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- MCT8 deficiency, MCT8, thyroid hormone transport, thyroid hormone analogs, hypermetabolism, psychomotor retardation, serum thyroid hormones, thyroid-stimulating hormone, sex hormone-binding globulin, children, compassionate use
- MeSH terms
- Brain, Cardiotonic Agents, Child Development, Child, Preschool, Diiodothyronines, Diseases in Twins, Humans, Infant, Male, Muscle Hypotonia, Muscular Atrophy, Propionates, Psychomotor Performance, Thyroid Function Tests, Multicenter Studies as Topic, Monocarboxylic Acid Transporters, Symporters, X-Linked Intellectual Disability, Mental Retardation, X-Linked, Compassionate Use Trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
